See referenced original article on pages 3159–64, this issue.
Advanced conventional chondrosarcomas: Time to revisit treatments and clinical research for what is not an indolent disease
Article first published online: 3 JUL 2014
© 2014 American Cancer Society
Volume 120, Issue 20, pages 3103–3104, October 15, 2014
How to Cite
Italiano, A. (2014), Advanced conventional chondrosarcomas: Time to revisit treatments and clinical research for what is not an indolent disease. Cancer, 120: 3103–3104. doi: 10.1002/cncr.28842
- Issue published online: 3 OCT 2014
- Article first published online: 3 JUL 2014
- Manuscript Accepted: 29 APR 2014
- Manuscript Revised: 26 APR 2014
- Manuscript Received: 7 APR 2014
Medical and surgical oncologists involved in the management of patients with sarcoma know well that the management of those with recurrent chondrosarcoma is quite challenging. In light of the currently available data, anthracycline-based chemotherapy and radiotherapy represent reasonable options for chondrosarcoma patients not eligible to a clinical trial with good performance status and who have unresectable metastatic or locally advanced disease, respectively.